Cancer Genetics Department, Mater Private Hospital, 73 Eccles St, Dublin 7, Ireland,
Fam Cancer. 2013 Dec;12(4):741-7. doi: 10.1007/s10689-013-9652-9.
Genetic testing of an Irish kindred identified an exonic nucleotide substitution c.1664T>C (p.Leu555Pro) in the MLH1 mismatch repair (MMR) gene. This previously unreported variant is classified as a "variant of uncertain significance" (VUS). Immunohistochemical (IHC) analysis and microsatellite instability (MSI) studies, genetic testing, a literature and online MMR mutation database review, in silico phenotype prediction tools, and an in vitro MMR activity assay were used to study the clinical significance of this variant. The MLH1 c.1664T>C (p.Leu555Pro) VUS co-segregated with three cases of classic Lynch syndrome-associated malignancies over two generations, with consistent loss of MLH1 and PMS2 protein expression on IHC, and evidence of the MSI-High mutator phenotype. The leucine at position 555 is well conserved across a number of species, and this novel variant has not been reported as a normal polymorphism in the general population. In silico and in vitro analyses suggest that this variant may have a deleterious effect on the MLH1 protein and abrogate MMR activity. Evidence from clinical, histological, immunohistochemical, and molecular genetic data suggests that MLH1 c.1664T>C (p.Leu555Pro) is likely to be the pathogenic cause of Lynch syndrome in this family.
对一个爱尔兰家族的基因测试发现 MLH1 错配修复 (MMR) 基因中的外显子核苷酸替换 c.1664T>C (p.Leu555Pro)。这个以前未报道的变体被归类为“意义不确定的变体” (VUS)。免疫组织化学 (IHC) 分析和微卫星不稳定性 (MSI) 研究、基因测试、文献和在线 MMR 突变数据库综述、计算机表型预测工具以及体外 MMR 活性测定用于研究该变体的临床意义。MLH1 c.1664T>C (p.Leu555Pro) VUS 与两代中的三个经典 Lynch 综合征相关恶性肿瘤共分离,IHC 上 MLH1 和 PMS2 蛋白表达一致缺失,并且存在 MSI-High 突变体表型的证据。位置 555 的亮氨酸在许多物种中都得到很好的保守,并且该新变体尚未被报道为一般人群中的正常多态性。计算机和体外分析表明,该变体可能对 MLH1 蛋白具有有害影响并废除 MMR 活性。来自临床、组织学、免疫组织化学和分子遗传学数据的证据表明,MLH1 c.1664T>C (p.Leu555Pro) 很可能是该家族 Lynch 综合征的致病原因。